As of 2024-12-14, the EV/EBITDA ratio of Isofol Medical AB (publ) (ISOFOL.ST) is -6.19. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ISOFOL.ST's latest enterprise value is 270.69 mil SEK. ISOFOL.ST's TTM EBITDA according to its financial statements is -43.70 mil SEK. Dividing these 2 quantities gives us the above ISOFOL.ST EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.7x - 15.8x | 11.6x |
| Forward P/E multiples | 11.3x - 15.3x | 13.6x |
| Fair Price | (2.42) - (3.50) | (2.77) |
| Upside | -204.5% - -250.9% | -219.5% |
| Date | EV/EBITDA |
| 2024-12-11 | -5.90 |
| 2024-12-10 | -5.86 |
| 2024-12-09 | -6.93 |
| 2024-12-06 | -7.47 |
| 2024-12-05 | -7.19 |
| 2024-12-04 | -7.71 |
| 2024-12-03 | -7.56 |
| 2024-12-02 | -8.15 |
| 2024-11-29 | -8.67 |
| 2024-11-28 | -8.26 |
| 2024-11-27 | -8.17 |
| 2024-11-26 | -8.52 |
| 2024-11-25 | -8.71 |
| 2024-11-22 | -8.49 |
| 2024-11-21 | -8.69 |
| 2024-11-20 | -9.89 |
| 2024-11-19 | -9.72 |
| 2024-11-18 | -8.28 |
| 2024-11-15 | -8.15 |
| 2024-11-14 | -8.21 |
| 2024-11-13 | -8.21 |
| 2024-11-12 | -8.74 |
| 2024-11-11 | -9.26 |
| 2024-11-08 | -9.71 |
| 2024-11-07 | -9.65 |
| 2024-11-06 | -9.93 |
| 2024-11-05 | -10.56 |
| 2024-11-04 | -11.18 |
| 2024-11-01 | -10.98 |
| 2024-10-31 | -11.59 |
| 2024-10-30 | -11.39 |
| 2024-10-29 | -11.11 |
| 2024-10-28 | -11.57 |
| 2024-10-25 | -11.77 |
| 2024-10-24 | -11.15 |
| 2024-10-23 | -10.96 |
| 2024-10-22 | -12.33 |
| 2024-10-21 | -10.37 |
| 2024-10-18 | -12.22 |
| 2024-10-17 | -12.53 |
| 2024-10-16 | -9.89 |
| 2024-10-15 | -9.91 |
| 2024-10-14 | -8.25 |
| 2024-10-11 | -8.71 |
| 2024-10-10 | -7.56 |
| 2024-10-09 | -7.45 |
| 2024-10-08 | -7.30 |
| 2024-10-07 | -7.27 |
| 2024-10-04 | -7.34 |
| 2024-10-03 | -7.30 |